Correspondence dscastro@igc.gulbenkian.pt In Brief Vasconcelos et al. find that the transcription factor MyT1 promotes neuronal differentiation downstream the proneural factor Ascl1. MyT1 represses the transcription of Notch signaling components and targets genes, including important regulators of the neural progenitor program. Thus, Ascl1 activates differentiation genes while repressing the progenitor program via MyT1.
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INTRODUCTION
The generation of neurons in the developing vertebrate nervous system requires the progression through a succession of distinct cellular states. These transitions have been particularly well characterized in the embryonic telencephalon, where radial glia (RG) cells located in the ventricular zone (VZ) have characteristics of neural stem cells and constitute the major progenitor type during the neurogenic period (Gö tz and Huttner, 2005) . Upon division, an RG cell can give rise to another RG cell and either a neuronal committed intermediate progenitor (IP) or a post-mitotic neuron that migrate toward the subventricular zone (SVZ) and cortical plate (CP), respectively (Kriegstein and Alvarez-Buylla, 2009 ). These events are known to be coordinated, to large extent, by the opposing activities of proneural and Notch pathways.
Proneural transcription factors, such as Ascl1 (also known as Mash1), are both required and sufficient to induce a complete program of neuronal differentiation (Bertrand et al., 2002; Vasconcelos and Castro, 2014; Wilkinson et al., 2013) . While activating neuronal differentiation, proneural proteins induce the transcription of Notch ligands, such as Dll1. Dll1 interacts with a transmembrane Notch receptor in neighboring cells, resulting in cleavage of the Notch intracellular domain (NICD) by gamma-secretase and its nuclear translocation, forming a complex with the DNA-binding transcription factor Rbpj and additional coactivators. Direct targets of this complex include the transcriptional repressors Hes1 and Hes5, which repress the expression of proneural genes and neuronal differentiation via a process called lateral inhibition Louvi and Artavanis-Tsakonas, 2006) . The induction of differentiation by proneural factors requires, therefore, the simultaneous repression of Notch receptor activity in differentiating progenitors by mechanisms that remain poorly understood.
Myelin transcription factor 1 (MyT1 or NZF2) is the founding member of a family of zinc-finger proteins comprising also MyT1Like (MyT1L or NZF1) and MyT3 (NZF3 or St18) (Jiang et al., 1996; Kim and Hudson, 1992; Yee and Yu, 1998) . All factors are expressed with distinct patterns throughout the mouse developing nervous system. In situ hybridization studies have described Myt1 expression in differentiating progenitors and post-mitotic neuronal precursors, in both CNS and peripheral nervous system, starting at the beginning of the neurogenesis period (Matsushita et al., 2002 (Matsushita et al., , 2014 . Evidence for a regulatory function of MyT1 in a neurogenic context was provided by functional studies in Xenopus embryos, where it counteracts lateral inhibition in synergy with the proneural factors X-Ngnr1, Xash3, or Xath5 (Bellefroid et al., 1996; Quan et al., 2004; Schneider et al., 2001) . In mouse, the analysis of MyT1-null embryos has failed to provide insights into the function of MyT1 in the nervous system, presumably due to the observed ectopic upregulation of other family members in this mouse model (Hudson et al., 2011; Wang et al., 2007) . More recently, the extensive use of MyT1L in neuronal reprogramming of mouse and human somatic cells (e.g., Pang et al., 2011 and Vierbuchen et al., 2010) has renewed the interest in understanding the function of MyT1 and its related factors in vertebrate neurogenesis.
Here, we identify MyT1 as a direct target of the proneural factor Ascl1 at the onset of neuronal differentiation, and we investigate the function of MyT1 at this critical stage by combining acute functional experiments in the mouse telencephalon with the characterization of its transcriptional program. We found that MyT1 binding occurs mostly at active regulatory regions in undifferentiated neural stem/progenitor cells and is associated with transcriptional repression genome-wide. We further show that MyT1 acts at multiple levels to antagonize the inhibitory activity of Notch signaling, targeting both Notch pathway components and downstream targets. Notably, MyT1 promotes the downregulation of Hes1, a determinant step for the onset of neurogenesis, by competing with Rbpj for binding to the Hes1 promoter. Our results reveal a function of Ascl1 in inhibiting Notch signaling cell-autonomously, showing how activation of neuronal differentiation is tightly coordinated with repression of the progenitor program.
RESULTS
Ascl1 Directly Activates the Transcription Factor MyT1
Several observations have suggested the zinc-finger transcription factor MyT1 may be under the regulation of Ascl1. Specifically, Myt1 expression is increased or decreased in expression profiling studies using DNA arrays upon Ascl1 gain and loss of function (GoF and LoF), respectively, both in mouse cultured neural stem/progenitor cells and in the embryonic telencephalon ( Figure S1 ) .
We started by analyzing the kinetics of MyT1 expression, using a cellular model of neurogenesis in which differentiation is triggered by the activation of an inducible version of Ascl1 protein (Ascl1-ERT2) in the neural stem cell line NS5 with 4-hydroxytamoxifen (Tam) . Upon Ascl1 induction, MyT1 protein levels increased, as measured by immunocytochemistry and western blot ( Figures 1A and 1B) . Co-localization of MyT1 with the neuronal marker B-III-Tubulin (TuJ1) indicated that MyT1 expression occurred in differentiating neurons (Figure 1A) . The increase in Myt1 expression occurred after the increase in Dll1 transcript, an early Ascl1 target gene, and preceded the increase in B-III-Tubulin transcript, an early neuronal marker that is also directly activated by Ascl1 (Castro et al., 2006 (Figure 1C) . Thus, the timing of MyT1 induction is consistent with MyT1 being directly controlled by Ascl1.
Effectively, visual inspection of the chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) enrichment profile of Ascl1-ERT2 in differentiating cells identified several peaks, corresponding to Ascl1 binding to active enhancer regions enriched for H3K4me1 and H3K27ac in the vicinity of the MyT1 gene (Figure 1D) . Some Ascl1-binding events (BEs) occurred in closed chromatin regions in proliferating progenitors, which became opened during neuronal differentiation, as assessed by DNase sequencing (DNase-seq) ( Figure 1D ). This feature is associated with Ascl1 targets that are expressed de novo during differentiation , and it may account for the late timing of MyT1 induction after Ascl1 expression. Ascl1 binding to Myt1 promoter was further validated by ChIP-qPCR in chromatin extracted from the developing ventral telencephalon ( Figure 1E ).
MyT1 Promotes Neurogenesis in the Mouse Telencephalon
Myt1 transcript is expressed in the germinal layers during the neurogenic period in scattered cells in the VZ, with highest expression in the SVZ (Matsushita et al., 2002 (Matsushita et al., , 2014 . In the ventral telencephalon, MyT1 protein expression domain largely overlapped with that of the neuronal marker TuJ1 ( Figure 1F) . At the cellular level, many, but not all, MyT1-expressing cells in the SVZ co-expressed TuJ1 ( Figure 1G ), suggesting MyT1 was expressed both in IPs and differentiating neurons. In addition, few MyT1-expressing cells were interspersed in the VZ co-expressing TuJ1 ( Figure 1G , arrowheads in upper panels). Although MyT1 and Ascl1 expression domains were mostly non-overlapping ( Figure 1F ), some cells co-expressing both factors could be found in the SVZ ( Figure 1G , arrowheads in bottom panels), as expected from Ascl1-expressing IPs. Overall, the expression pattern was consistent with MyT1 starting to be expressed at the transition from RG cells to differentiating neurons, either directly (VZ) or indirectly through the generation of IPs (SVZ). The persistent expression of MyT1 in post-mitotic neuronal precursors suggests a function also at later stages of neurogenesis.
We next investigated MyT1 function in the telencephalon by performing acute GoF and LoF experiments by in utero electroporation. We targeted the lateral ganglionic eminence (LGE) at embryonic day (E)12.5, a stage at which MyT1 is the only member of its family to be significantly expressed in germinal layers (Matsushita et al., 2002 (Matsushita et al., , 2014 . MyT1 overexpression resulted Data are shown as mean ± SD; n.s., p > 0.05; **p < 0.01, ***p < 0.001, and ****p < 0.0001, according to one-way ANOVA with Bonferroni correction for multiple testing (C) and Student's t test (E). See also Figure S1 . in more cells ($56% increase) leaving the VZ, and this was associated with an increase in TuJ1-expressing cells ($20% more) when compared to control conditions ( Figures 2B and 2C) . By contrast, knockdown of MyT1 with a small hairpin RNA (shRNA) expression vector (ShMyT1) (Figure 2A ) resulted in more cells remaining in the VZ ($85% increase) and fewer TuJ1-positive cells ($17.4% decrease) ( Figures 2B and 2C) . We analyzed if the concomitant induction of other family members could be compensating the extent of the phenotype observed, by knocking down MyT1 together with MyT1L or MyT3. Indeed, a significant enhancement of the phenotype was observed when combining shMyT1 with shMyT1L, both in number of cells retained in the VZ and in the number of TuJ1-positive cells (Figure S2) ; the combination with ShMyT3 did not increase significantly the phenotype triggered by shMyT1 alone. Altogether, these experiments demonstrate that MyT1 promotes neurogenesis in the developing mouse embryo.
MyT1 Functions as a Transcriptional Repressor during Neurogenesis
To understand the molecular basis of MyT1 function at the onset of differentiation, we characterized its target genes upon acute GoF in neural stem/progenitor cells. For this, we infected NS5 cells with a lentivirus expressing a doxycycline (Dox)-inducible HA-tagged version of MyT1, and we characterized the gene expression changes 4 hr post MyT1 induction using DNA arrays ( Figure S3 ). This identified 1,764 deregulated genes (p < 0.05), of which 57% were downregulated and 43% were upregulated (Table S1 ). We performed genome-wide mapping of MyT1 binding by ChIP-seq using an antibody against the HA-tag of MyT1, and we identified 7,615 BEs (q < 10 À2 ) associated with 4,448 unique genes following a nearest gene annotation (Table  S2) . A de novo search found the MyT1-binding motif (Gamsjaeger et al., 2008; Kim and Hudson, 1992) to be enriched at peak summits, with peaks with one or multiple motifs significantly enriched when compared to a control dataset ( Figures 3A-3C ). In addition, a compound Rfx/Rbpj motif, E box (bHLH) and Sox DNA-binding motifs were also overrepresented. Hierarchical clustering of MyT1 peaks according to the presence of these motifs revealed their occurrence was largely mutually exclusive ( Figure S4A ). Although the largest group bore the MyT1 motif, the data suggest that many MyT1 peaks result from indirect recruitment of MyT1 by other TFs.
Previous reports have implicated MyT1 both in transcriptional activation and repression (Bellefroid et al., 1996; Hu et al., 2013; Romm et al., 2005; Wang et al., 2008; Yokoyama et al., 2014) . To gain an insight into the global transcriptional response mediated by MyT1, we integrated the location analysis of MyT1 with the expression profiling to find that 14% of sites are associated with a deregulated gene. Strikingly, MyT1 BEs were statistically significantly associated with downregulated genes (p < 3.45 3 10 À51 ), whereas such association with upregulated genes was not found ( Figure 3D ). Notably, this differential association with downregulated genes was maintained when considering only peaks containing the MyT1 motif, or those without it ( Figure S4B ), suggesting that all types of MyT1 BEs are associated with repression of gene expression. We next determined the fractions of up-and downregulated genes associated with at least one MyT1 BE (direct targets), considering increasing p value cutoffs for MyT1 binding (Figure 3E ). We found that downregulated genes were strongly enriched for MyT1 direct targets, in contrast to upregulated genes ( Figure 3E , compare Down/MyT1 with Up/MyT1), and that such enrichment was statistically significant ( Figure 3E , compare Down/MyT1 with Down/Random), confirming that MyT1 binding is associated with gene repression genome-wide.
Genome-wide maps of histone modifications in proliferating NS5 cells (Mikkelsen et al., 2007; showed significant enrichment of H3K27ac, H3K4me1, and H3K4me3 at MyT1 BEs, as compared to random genomic regions (while no enrichment of the repressive mark H3K27me3 was found) ( Figure 3F ). In addition, most MyT1 BEs were found within intergenic or intronic regions, with a smaller but significant fraction occurring at gene promoters ( Figure 3G ). These results suggest that MyT1 binds to distal enhancer and promoter regions bearing active marks in neural stem/progenitor cells, and they are in line with MyT1's role as a transcriptional repressor at onset of differentiation.
MyT1 Represses Notch Pathway Components and Regulators of the Neural Progenitor Program
We next assessed the expression of the identified MyT1 targets (bound and downregulated) at distinct stages of the neuronal lineage, using expression profiling datasets representative of various layers of the E14.5 mouse embryonic cortex . Notably, most MyT1 direct targets (69.0%) were downregulated during neuronal differentiation in vivo, as indicated by a decrease in expression from VZ to SVZ or CP (Figure 3H ). In addition, their absolute levels of expression were highest at VZ, when compared to SVZ and CP ( Figure 3I) .
To investigate the function of MyT1 direct targets, we performed gene ontology (GO) analysis on a high-confidence list of 402 MyT1 targets (bound and repressed by MyT1) (Table  S3) . Enriched terms (GO biological processes) suggested a role in maintenance of a progenitor state (negative regulation of neuron differentiation, positive regulation of cell proliferation, and cell-cycle process), and they were associated with Notch pathway genes (e.g., Notch1, Lfng, Dtx4, and Hes1) ( Figure 3J ; Table S4 ). In addition, MyT1 targets encoded important transcriptional regulators (regulation of transcription from RNA polymerase II [Pol II] promoter) ( Figure 3J ) of the neural progenitor program, such as Sox2, Id3, and Olig1 (Bai et al., 2007; Englund et al., 2005 ; Gó mez-Ló pez et al., 2011) (Figures 3K  and 3L ; Table S4) .
MyT1 has been shown to physically interact with the histone demethylase LSD1 in a complex that contains CoREST and promotes transcriptional repression (Yokoyama et al., 2014) . To address if LSD1 is recruited by MyT1 to the abovementioned targets associated with a MyT1 motif, we performed anti-LSD1 ChIP-qPCR. We observed a substantial increase of LSD1 recruitment to MyT1 target sites upon MyT1 GoF, supporting a role for this histone demethylase in MyT1-mediated transcriptional repression in neural progenitor cells ( Figure 3M ).
MyT1 Promotes Neurogenesis by Counteracting Notch-Signaling Activity
Given the prominence of Notch-related genes among MyT1 targets and in line with previous findings (Bellefroid et al., 1996; Hu et al., 2013; Romm et al., 2005; Wang et al., 2008; Yokoyama et al., 2014) , we tested if MyT1 can counteract the inhibitory effect of Notch signaling in neurogenesis. We infected NS5 cells with lentiviruses expressing Ascl1, MyT1, and a membranebound dominant active version of the Notch1 receptor, whose cleavage is independent of a ligand/receptor interaction (Act Notch). As expected, Ascl1 expression induced the generation of TuJ1-positive neurons with a concomitant decrease of Sox2 expression (Berninger et al., 2007; Farah et al., 2000; Nakada et al., 2004) , and this effect was inhibited by the co-expression of Act Notch (Gaiano et al., 2000) ( Figure 4A ). Importantly, MyT1 alone did not trigger neuronal differentiation, but its coexpression with Ascl1 overcame the inhibition by Act Notch, as observed by a rescue of the number of TuJ1-positive cells to levels similar to those obtained with Ascl1 alone (with Sox2 expression following a similar trend). In addition, a strong increase in the differentiation activity of Ascl1 alone was observed when both factors (Ascl1 + MyT1) were co-expressed ( Figures  4A and 4B, respectively) . Altogether, our results suggest that MyT1 alone is not able to promote neuronal differentiation but that it enhances the activity of the proneural factor by counteracting the inhibitory activity of the Notch pathway.
We next tested whether MyT1 could similarly counteract Notch signaling in vivo by co-electroporating MyT1 and Act Notch expression vectors in the dorsal telencephalon. As expected, expression of Act Notch inhibited endogenous neurogenesis, resulting in the retention of electroporated cells closer to the ventricular surface and in a decreased number of cells expressing the neuronal marker Satb2 ( Figures 4B and 4C ), whereas MyT1 overexpression had the opposite effect ( Figures  4B and 4C) . Notably, co-expression of Act Notch and MyT1 rescued significantly the Act Notch phenotype ( Figures 4B and  4C) . Overall, these experiments support the conclusion that MyT1 counteracts Notch signaling during neurogenesis.
MyT1 Counteracts Notch Activation of Hes1 Expression
Considering the well-established role of Hes1 as a downstream effector of Notch signaling in neurogenesis (Artavanis-Tsakonas et al., 1999; Shimojo et al., 2008) , we next focused on the regulation of this MyT1 target gene. Analysis of the MyT1 ChIP-seq profile showed strong enrichment at the Hes1 proximal promoter region, centered on three evolutionarily conserved MyT1 motifs ( Figure 5A ). Strikingly, these motifs were found in tandem, and partially overlapping, with three Rbpj-binding motifs (TC box) previously shown to mediate the regulation of Hes1 by Notch/ Rbpj (Arnett et al., 2010; Jarriault et al., 1995; Nam et al., 2007) ( Figure 5B ). To test the ability of MyT1 to bind to its cognate motifs, we performed an electrophoretic mobility shift assay (EMSA) using a Hes1 oligonucleotide probe spanning the MyT1 motifs or mutated versions. MyT1 was able to directly bind to this Hes1 promoter probe, as shown by the formation of a large DNA/ protein complex ( Figure 5C ). The formation of this complex was strongly reduced or abolished when each of the MyT1 motifs was disrupted separately or simultaneously, respectively, suggesting cooperative binding of MyT1 to the three sites.
We next investigated whether MyT1 could counteract the activity of Notch signaling on a luciferase reporter construct containing the Hes1 proximal promoter region spanning all MyT1 and Rbpj sites (pHes1::Luc) (Nishimura et al., 1998) . A transcriptional assay in transfected P19 cells showed Act Notch strongly activates the Hes1 promoter, while co-expression of MyT1 completely abrogated this activity ( Figure 5D ). To test if the observed effect of MyT1 is dependent on DNA binding, we performed mutagenesis on the MyT1-binding sites. Mutations were designed so as to minimize any effect on Notch activation, resulting in promoter constructs that still responded, albeit less strongly, to Act Notch ( Figure 5E ). Disruption of individual binding sites partially impaired the activity of MyT1 (Figure 5F ), while simultaneous disruption of the three sites (BS1 + 2 + 3) had a stronger effect readily observed when lower ratios of MyT1/Act Notch were used ( Figure 5G) . Similar results were obtained using a dominant active version of Rbpj fused to the VP16 activation domain (RBPJ-VP16) ( Figure 5H ), further supporting that MyT1 regulates Hes1 at the promoter level. Importantly, no other transcription factor tested was able to counteract Act Notch activity on Hes1 promoter ( Figure S5 ). Altogether, we concluded that MyT1 counteracts the activity of the Notch/Rbpj complex on the Hes1 promoter via a mechanism that depends on binding to the three MyT1-binding sites.
Next, we analyzed MyT1 protein and Hes1 transcript expression patterns in the embryonic mouse telencephalon by double immuno/in situ hybridization, and we concluded these are largely non-overlapping ( Figure 6A ). To further investigate this with single-cell resolution, we re-examined the molecular signatures of 96 E11.5 dorsal telencephalic neural stem/progenitor cells obtained by single-cell RNA sequencing (RNA-seq) . Profiling using principal component 2 (PC2), which orders cells through differentiation according to markers that reflect the progression of cortical neurogenesis , showed an inverse correlation between Myt1 and Hes1 expression ( Figure 6B , upper graph), with a Spearman correlation coefficient of reads per kilobase per million mapped reads (RPKM) levels of À0. 407 . In spite of this, examination of absolute RPKM levels showed that co-expression of both genes was detected in a small but significant fraction of cells, suggesting the onset of Myt1 expression occurs in cells that still express Hes1 ( Figure 6B, bottom panel) . Thus, MyT1 expression is inversely correlated, but partially overlapping, with that of Hes1, which is consistent with MyT1 playing a determinant role in switching off Hes1 transcription at the onset of neurogenesis.
MyT1 Represses Many Notch/Rbpj Transcriptional Targets
The overrepresentation of a putative Rbpj-binding motif at MyT1 target sites ( Figure 3A) suggests the direct control of Notch target genes by MyT1 may extend beyond the regulation of Hes1. To investigate this, we compared the transcriptional Data are shown as mean ± SD; n.s., p > 0.05; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, according to one-way ANOVA with Bonferroni correction for multiple testing (A) and Student's t test (B'-C').
changes observed in our MyT1 GoF model with those that take place upon exposure of NS5 cells to the pharmacological inhibitor of gamma-secretase LY411575 (LY), (Lanz et al., 2004) , as assessed by RNA sequencing (RNA-seq) (Table S5) . When considering a high-confidence list of genes deregulated upon MyT1 induction (p < 0.01, n = 90), the vast majority (81%) was also deregulated upon LY treatment, with all these but two genes changing in the same direction ( Figure 7A) . Notably, this same trend (expression of common deregulated genes changes in same direction) was maintained when decreasing the stringency cutoff for deregulation by MyT1 (p < 0.05, n = 1,612), or simulta- Figure S5 .
neously increasing the stringency cutoff for deregulation upon LY treatment (q < 0.01, n = 1,612) ( Figure 7A ). Thus, MyT1 expression induces a global change in gene expression that resembles that triggered by the inhibition of Notch signaling. Considering the short time points (4 hr) at which both expression profiling experiments were performed, it is likely that many genes downstream Notch are direct MyT1 targets. In agreement with this, we found a much stronger statistical association of MyT1 BEs with genes downregulated by LY than with upregulated ones (p < 1.6 3 10 À70 versus p < 1.1 3 10 À8 ) (Figure 7B) . To evaluate the extent to which MyT1 represses genes directly activated by the Notch/Rbpj complex, we performed genome-wide mapping of Rbpj in NS5 cells by ChIP-seq, resulting in the identification of 15,281 BEs (q < 10 À2 ) (Table S6; Figure 7D ) associated with 9,215 unique genes. As expected, a de novo search for DNA motifs enriched at Rbpj BEs found the TC box to be the most enriched motif, in addition to an E box (bHLH) and the compound Rfx/Rbpj motif ( Figure 7C) . A strong Rbpj-sequencing signal was found at genomic regions centered at MyT1 peak summits, confirming that MyT1 often binds in close vicinity to Rbpj (Figure 7E) , as illustrated for several targets (Figures 5A and 7D) . Notably, most (80.4%) of MyT1 direct targets identified were also bound by Rbpj. MyT1 and RBPJ binding and their opposite effects in target gene expression were validated for several genes ( Figures 3K, 3L, 7F , and 7G). Most significantly was the ability of both pathways to oppositely regulate the expression of Notch1, further validated by the ability of MyT1 to counteract the activation of Notch1 gene promoter by Act Notch in a transcriptional assay (Figures S6A-S6C ). In conclusion, MyT1 can counteract the Notch pathway at distinct levels, repressing Notch-signaling components and many of its downstream targets.
DISCUSSION
In spite of its identification two decades ago, little progress has been made toward understanding the function of the zinc-finger factor MyT1 in vertebrate neurogenesis. After initial studies in Xenopus embryos suggested X-MyT1 promotes neurogenesis by counteracting lateral inhibition (Bellefroid et al., 1996) , a confirmation of such model using mouse genetics has been hampered by functional redundancy with other family members (Wang et al., 2007) . In addition, no molecular basis has been ever established for MyT1 function, to large extent due to the lack of identified target genes. Here we provide evidence of a neurogenic role for MyT1 in the developing mouse embryo, and we characterize its transcriptional program.
Activation of neuronal differentiation requires the concomitant repression of the gene expression program that operates in neural stem/progenitor cells, including the downregulation of the Notch transcriptional program (Imayoshi and Kageyama, 2014; Kageyama et al., 2008) . This is often attributed to decreased Notch input signaling from neighboring cells (Kawaguchi et al., 2008; Nelson et al., 2013) , which results in default repression of Notch target genes via the recruitment of corepressors by Rbpj. However, recent studies have reported that IPs exhibit attenuated Rbpj signaling as compared to RG cells, and they are unable to induce the expression of Hes genes upon activation of the Notch receptor (Kawaguchi et al., 2008; Mizutani et al., 2007; Nelson et al., 2013) . This suggests the existence of cell-autonomous mechanisms to inhibit the Notch program at the onset of differentiation, which could be explained by the regulation of Notch target genes by transcription factors such as MyT1. In addition, MyT1 interacts with the Notch pathway also by regulating various pathway components. Most notably, the repression of Notch1 receptor gene may lead to an overall decrease of Notch-signaling levels by MyT1. In agreement with this, the expression of Hes5, a well-established readout of Notch signaling, was strongly downregulated upon MyT1 expression with no apparent binding of MyT1 to its promoter region ( Figures 3L, S6D, and S6E) .
Among the targets identified, Hes1 is likely to be a major effector of MyT1 in neurogenesis. Hes1 expression intrinsically oscillates in proliferating neural stem/progenitor cells, by a mechanism that relies on its activation by Notch signaling. It is believed that the onset of differentiation depends critically on the sustained downregulation of Hes1 expression; however, the mechanisms that repress Hes1 in this context are poorly understood (Imayoshi and Kageyama, 2014; Imayoshi et al., 2013) . The cis architecture of the Hes1 promoter, where MyT1 and Rbpj sites are found interspersed and partially overlapping, was revealed to be a very efficient mechanism to counteract Notch activity. This feature may be unique to Hes1, as we did not find a similar cis architecture at other regulatory regions targeted by both pathways. It has been shown that MyT1L cooperates with Ascl1 in reprogramming mouse embryonic fibroblasts (MEFs) into induced neurons (Vierbuchen et al., 2010) . Although it is not clear what the levels of canonical Notch signaling are in MEFs, Hes1 expression is well documented in this cellular context. MyT1 family members have high sequence homology within the zinc-finger domains, and all have been shown to recognize the MyT1 DNA-binding motif (Bellefroid et al., 1996; Jiang et al., 1996; Yee and Yu, 1998) . Therefore, it is possible that MyT1L functions, at least in part, by repressing Hes1 during reprogramming. In support of this, we found that MyT1L counteracts the Notch activation of Hes1 promoter with the same efficiency as MyT1 ( Figure S7A ). In addition, ChIP-qPCR analysis of an HA-tagged version of MyT1L revealed a strong enrichment at Hes1 proximal promoter soon after ectopic expression in MEFs ( Figure S7B) .
The broad expression of MyT1 in the embryonic nervous system (Matsushita et al., 2014) , together with the importance of Notch signaling in neurogenesis, suggests that the regulatory events we identified in the telencephalon may occur pan-neuronally throughout the embryonic nervous system. In addition, while our study focuses on the function of MyT1 at the onset of neuronal differentiation, further research should also address the function of MyT1 at later stages along the neuronal lineage.
EXPERIMENTAL PROCEDURES
Immunohistochemistry and In Situ RNA Hybridization Embryonic brains were processed for in situ hybridization or immunostaining as previously described . For double in situ hybridization/ immunohistochemistry, frozen sections were treated as for in situ hybridization until the last post-fixation step, before immunostaining. The Hes1 probe was produced from the plasmid pBluescriptII SK-Hes1. NS5 cells were grown on glass coverslips coated with poly-L-Lysine (Sigma-Aldrich) and fixed with 4% formaldehyde for 10 min. See the Supplemental Experimental Procedures for antibody dilutions used. Bright-field and fluorescent images of fixed sections and coverslips were acquired using the microscope Leica DMRA2 or the laser-scanning confocal microscope Zeiss LSM510 Meta.
In Utero Electroporation
Mouse MyT1 cDNA (Nielsen et al., 2004) and AcNotch coding sequences were cloned upstream of an internal ribosomal entry site (IRES) and an nuclear localization signal (NLS)-tagged GFP in the pCAG expression vector (Niwa et al., 1991) . Control and shRNA plasmids used (Sigma-Aldrich) were pLKO.1 scramble shRNA (Addgene 1864), pLKO MyT1 shRNA (TRCN0000081610), pLKO MyT1L shRNA (TRCN0000012109), and pLKO MyT3 shRNA (TRCN0000042479). Electroporation in utero was employed at E12.5 or E13.5 to deliver expression vectors (1 ml DNA plasmid corresponding to 3 mg mixed with 0.03% fast-green dye in PBS) to the ventricular RG cells of mouse embryos, as previously described (Saito, 2006; Sessa et al., 2008) . All experiments were conducted upon the approval and following the guidelines of animal care and use committees from San Raffaele Scientific Institute (SRSI) and Instituto Gulbenkian de Ciência (IGC).
Culture and Infection of NS5 Cells NS5 (Conti et al., 2005) and NS5-Ascl1-ERT2 cells were cultured in mouse Neurocult NSC basal medium supplemented with mouse Neurocult NSC proliferation supplement (STEMCELL Technologies), penicillin-streptomycin (100 U/mL) (Gibco), epidermal growth factor (EGF, 10 ng/mL) (PeproTech), basic FGF (10 ng/mL) (PeproTech), and laminin (1 mg/mL) (Sigma-Aldrich). For expression profiling and ChIP, NS5-MyT1-HA/GFP TetON cells were generated upon infection with MyT1-HA TetON-FUW, eGFP TetON-FUW, and M2rtTA TetON-FUW lentiviruses and were further expanded. When indicated, cells were treated with 50 nM Tam (Sigma-Aldrich), 2 mg/mL Dox hyclate (Sigma-Aldrich), or 10 nM LY (Lanz et al., 2004) . Replication-incompetent lentiviruses were produced by transient transfection of HEK293T cells with TetON-FUW vectors co-transfected with psPAX2 and pCMV-VSVG. Lentiviral particles were concentrated from supernatant by ultracentrifugation at 9,000 3 g for 4 hr and resuspended in 0.1% BSA PBS.
Gene Expression, DNA Microarrays, and RNA-Seq Gene expression analysis of cultured NS5 cells by real-time qPCR with PerfeCTa SYBR Green FastMix, ROX (Quanta Biosciences) was carried out according to the manufacturer's instructions on an ABI7900 HT machine (Applied Biosystems), using cDNA produced with High Capacity RNA-tocDNA Master Mix (Applied Biosystems) after Trizol RNA extraction (see the Supplemental Experimental Procedures for primers). Microarray analysis was performed on biological triplicates of NS5 MyT1-HA TetON cells 0 and 4 hr post-Dox induction. RNA concentration and purity were confirmed using Agilent 2100 Bioanalyzer with RNA Nano Kit (Agilent Technologies). RNA (100 ng) was processed with Ambion WT Expression Kit (Life Technologies) and hybridized to the Affymetrix Mouse Gene 1.0 ST Array. CEL files were analyzed using Chispter software (version 3.1.0, Kallio et al., 2011) using RNA normalization and empirical Bayes two-group test with Benjamini-Hochberg post hoc for p value correction. Samples used for RNA-seq analysis were obtained from biological triplicates of NS5 0 and 4 hr post-LY treatment, and total RNA was extracted as described above. The sequencing library was prepared according to the TruSeq RNA sample preparation version 2 protocol (Illumina) and sequenced on an Illumina HiSeq 2000. Raw reads were aligned to NCBI37 (mm9) mouse genome using Tophat2 version 2. 0.3 (Kim et al., 2013) . Pairwise analysis of differential gene expression was performed with cuffdiff version 2.1.1 using fragment bias and multi-read corrections . Genomic sequence and gene annotation were obtained from ENSEMBL (May 2012, version 67).
ChIP and ChIP-Seq Ascl1 ChIP from embryonic telencephalon was performed as previously described . NS5 cells were fixed sequentially with 2 mM di(N-succimidyl) glutarate and 1% formaldehyde in PBS and lysed, sonicated, and immunoprecipitated as described previously , using anti-HA (ab1424, Abcam), anti-Rbpj (D10A4, Cell Signaling Technology), or anti-LSD1 (ab17721, Abcam) antibodies. DNA sequences were quantified by real-time PCR (see the Supplemental Experimental Procedures for primers). For sequencing, DNA libraries were prepared from 10 ng immunoprecipitated DNA according to the manufacturer's protocol. Paired-end sequencing was performed using MySeq. Raw reads were mapped to the mouse genome (NCBI37/mm9) with Bowtie version 0.12.7 (Langmead et al., 2009) . Data were processed further with MACS version 1.4.1 (Zhang et al., 2008) to define the locations of BEs. Further details of data processing are described in the Supplemental Experimental Procedures. Data are shown as mean ± SD; n.s., p > 0.05; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001, according to Student's t test (F and G). See also Figure S6 .
In Vitro Binding and Transcriptional Assays EMSAs were performed as described previously (Castro et al., 2006) , using probes (Supplemental Experimental Procedures) labeled with [g-32P] ATP (PerkinElmer) using T4 polynucleotyde kinase (New England Biolabs). Control, MyT1, and RBPJ proteins produced by coupled in vitro transcription and translation in rabbit reticulocyte lysates (TNT, Promega) were incubated with probe in 20-mL binding reactions (15% glycerol, 20 mM HEPES [pH 7.9], 5 mM MgCl 2 , 50 mM KCl, 0.1 mM ZnSO 4 , 0.01% Triton X-100, 10 mM DTT, 5 mM PMSF, and 0.2 mg/uL herring sperm DNA; Sigma-Aldrich D7290) for 20 min at room temperature (RT). Reporter gene assays in transfected P19 cells were performed as previously described . Oligonucleotides used to mutate Hes1::Luc are described in the Supplemental Experimental Procedures.
Statistical Procedures
Where indicated, data from at least three (qPCR assays) or four (luciferase assays) biological replicates are presented as mean ± SD. For in utero electroporations, >500 cells from at least three sections were counted, using three embryos per condition. Differentiation in culture was scored counting >1,500 cells from three coverslips per condition. In all cases, statistical significance was calculated by performing a two-tailed, unpaired Student's t test or one-way ANOVA test with Bonferroni correction (see figure legends).
ACCESSION NUMBERS
The accession numbers for all genomic datasets reported in this paper are Array Express (http://www.ebi. Tables   Table S1 . Genes deregulated 4h after MyT1 GoF in NS5 cells (related to Figure 3) . Table S2 . Genomic coordinates of MyT1-HA binding events determined by ChIP-Seq (related to Figure 3) . Table S3 . Genes bound and repressed by MyT1 GoF (related to Figure 3) . Table S4 . Identity of MyT1 target genes associated with enriched Gene Ontology terms (related to Figure 3 ) Table S5 . Expression profiling dataset upon Notch inhibition (related to Figure 5 ). MyT1L-HA TetON-FUW An HA-tag oligonucleotide was inserted into the pCAG-MyT1L by PCR amplification using primers containing the HA-tag, STOP codon, one EcoRI site and one BglII site. The amplified fragment and the pCAG-MyT1L were digested with SacI and BglII. MyT1L-HA was excised from pCAG-MyT1L-HA vector using EcoRI and cloned into TetON-FUW.
List of Supplemental
Site-directed mutagenesis of pHes1::Luc The mutations on the MyT1 BSs on the Hes1 promoter luciferase reporter (pHes1::Luc) were generated by site-directed mutagenesis using the plasmid pHes1::Luc and the primers listed on the Table S7 . PCR reactions were performed with 50nM of each primer, 100ng of plasmid, 100μM dNTPs, 7.5U of Cloned Pfu polymerase and Pfu buffer with MgSO 4 (Stratagene). Reaction was run under the following cycling conditions: 1 cycle 95ºC/5min; 18 cycles (95ºC/50sec; 60ºC/50sec; 72ºC/10min); 1 cycle 72ºC/25min, followed by treatment with DpnI for 3-4h at 37ºC.
Table S7
Oligonucleotides used for site-directed mutagenesis of pHes1::Luc (related to Figure 5) searched are represented. Hierarchical clustering was plotted as heat maps with R/Bioconductor "hclust", "heatmap" packages. P(MyT1 ChIP-Seq)>10 -10 . 
Publicly available data sets used in this study
